A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Trial Profile

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Lenvatinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REFLECT
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 26 Sep 2017 According to an Eisai Inc media release,based on the results from this trial the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for lenvatinib (marketed as Lenvima) for the potential use in the first-line treatment of patients with hepatocellular carcinoma (HCC), commonly referred to as liver cancer.
    • 19 Sep 2017 According to an Eisai Co Ltd media release, results of subgroup analysis of patients with hepatitis B virus (HBV) coinfection were presented during the 11th Annual Conference of the International Liver Cancer Association (ILCA).
    • 19 Sep 2017 Results of subgroup analysis of patients with hepatitis B virus (HBV) coinfection, published in an Eisai Co Ltd media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top